PayPal Holdings, Inc.
Stocks
Pfizer, Inc.
Stocks
PayPal Holdings, Inc. vs Pfizer, Inc.: An Expert Financial and Market Performance Comparison
Last updated: June 2, 2026
Summary
PayPal Holdings Inc. and Pfizer Inc. operate in vastly different sectors, with PayPal excelling in financial technology and Pfizer leading in healthcare innovation. While PayPal boasts a higher earnings per share (EPS) of 5.33 compared to Pfizer's 1.31, Pfizer's market capitalization of approximately $146 billion significantly surpasses PayPal's $39.86 billion. This comparison highlights distinct strengths: PayPal's robust revenue and high dividend yield favor investors seeking growth and income, whereas Pfizer's lower beta indicates higher stability for risk-averse investors.
Key Differences at a Glance
| Aspect | PayPal Holdings, Inc. | Pfizer, Inc. | Winner |
|---|---|---|---|
| Market Capitalization | $39.86 billion | $146 billion | Pfizer, Inc. |
| Price-to-Earnings (PE) Ratio | 8.48 | 19.56 | PayPal Holdings, Inc. |
| Dividend Yield | 1.25% | 6.57% | Pfizer, Inc. |
| Beta (Market Volatility) | 1.395 | 0.305 | Pfizer, Inc. |
| Revenue | $33.73 billion | $63.32 billion | Pfizer, Inc. |
Market Capitalization: Pfizer's market cap is over three times larger than PayPal's, reflecting its dominant position in the healthcare sector and broader revenue base.
Price-to-Earnings (PE) Ratio: PayPal's lower PE ratio suggests it is relatively undervalued compared to Pfizer, which has a higher PE, indicating higher growth expectations or overvaluation.
Dividend Yield: Pfizer offers a significantly higher dividend yield, making it more attractive for income-focused investors seeking regular dividend income in the healthcare sector.
Beta (Market Volatility): Pfizer has a lower beta, indicating its stock is less volatile and more stable during market fluctuations, an advantage for conservative investors.
Revenue: Pfizer's revenue surpasses PayPal's by nearly double, reflecting its extensive product portfolio and global healthcare market reach.
Detailed Analysis
PayPal Holdings, Inc. and Pfizer, Inc. operate in fundamentally different sectors, making their financial metrics indicative of contrasting business models. PayPal's revenue of $33.73 billion, combined with an EPS of 5.33 and a PE ratio of approximately 8.48, signals a company that is valued relatively low compared to its earnings, suggesting potential undervaluation or strong growth prospects in digital payments and credit services. Its market capitalization of about $39.86 billion, although smaller than Pfizer's, demonstrates a significant presence within the financial technology landscape.
Conversely, Pfizer's revenue of $63.31 billion, nearly double PayPal's, underscores its position as a healthcare giant. Its PE ratio of approximately 19.56 indicates the market expects higher future earnings growth, reflected in its substantial market cap of around $146 billion. Pfizer's lower beta of 0.305 emphasizes its stability amidst market volatility, which is typical for healthcare stocks that tend to be less cyclical. Notably, Pfizer's dividend yield of 6.57% is considerably higher than PayPal’s 1.25%, appealing to income investors looking for consistent dividend payments.
The disparity in market caps and revenue highlights the fundamental industry differences. While PayPal benefits from high-margin services within the digital payments space, Pfizer's extensive drug portfolio and global reach translate into higher revenue and market valuation. The valuation metrics reinforce that Pfizer is viewed as a stable, income-generating asset, whereas PayPal is often seen as a growth-oriented investment with more volatility but potentially higher returns. The earnings per share favor PayPal, indicating efficient profit generation relative to its smaller size, but Pfizer’s diversified business model and higher revenue solidify its leadership in healthcare.
Ultimately, for expert investors, the choice hinges on risk appetite: Pfizer offers stability, consistent dividends, and a commanding market presence, while PayPal presents a promising undervalued opportunity with growth potential in the evolving digital economy.
Verdict
Pfizer, Inc. emerges as the overall winner for investors prioritizing stability, dividend income, and market dominance, given its higher market cap, revenue, and dividend yield. However, PayPal provides a compelling investment for growth-focused investors seeking undervaluation and technological innovation, evidenced by its lower PE ratio and higher EPS. The decision depends on individual risk tolerance and sector preference; for broad stability and income, Pfizer is superior, but for growth potential in digital finance, PayPal offers significant advantages.
Who Should Choose What
Choose PayPal Holdings, Inc. if...
Investors seeking undervalued stocks with growth potential in digital payments, high EPS, and dividend stability in the financial technology sector.
Choose Pfizer, Inc. if...
Investors looking for stability, high dividend income, and market leadership in healthcare, with a focus on large-cap, less volatile stocks.